GENE ONLINE|News &
Opinion
Blog

2021-10-08| Asia-PacificCOVID-19

Samsung Biologics Inks CDMO Deal with Enzolytics on HIV and COVID-19 Antibodies

by Tyler Chen
Share To
(Photo: Samsung Biologics)

U.S.-based Enzolytics this week inked a deal with one of the world’s biggest CDMO firms. Samsung Biologics will help develop and manufacture Enzolytics’s HIV and SARS-CoV-2 targeting monoclonal antibodies to accelerate the latter’s IND filing process.

 

Provide End-to-End CDMO Service

The Korean firm will provide services involving the development and manufacture of cell lines and clinical drug products. Their R&D Center located in San Francisco will manufacture a stable cell line while the Incheon headquarters will produce related trial materials.

“We chose to partner with Samsung Biologics because of Samsung Biologics’ extensive experience and expertise in developing, producing, and manufacturing Monoclonal Antibodies for Infectious Diseases and Oncology,” said Dr. Gaurav Chandra, Enzolytics’ Chief Operating Officer Research and Development. 

“This partnership marks a pivotal milestone for Enzolytics to significantly advance the clinical development of our universal, durable, broadly neutralizing Monoclonal Antibodies and reduce time to the clinic and offer the much-needed treatment for patients.”

The pair might advance the collaboration to include other products from Enzolytics.

 

Use AI to Develop Antibodies for Infectious Diseases

Enzolytics will carry out AI analysis to develop antibodies that target immutable locations on viruses that cause infectious diseases. Their antibody development on HIV therapeutics is the most advanced among all the indications. ITV-1, Enzolytics’s HIV therapeutics, is currently on trial in the EU.

The firm is also developing treatments for rheumatoid arthritis, influenza A and B, tetanus, and hepatitis (A, B, C). Now, their technology is also implemented in developing antibodies against the COVID-19 virus.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Amaran Biotech Crowned “Best CDMO in Automated Aseptic Filling” at Taiwan Biopharma Excellence Awards 2025!
2025-03-26
End of USAID Support in Kenya Raises Concerns Over Health Care and Livelihoods
2025-03-16
Controversy Surrounds Jay Bhattacharya’s Nomination as NIH Director
2025-03-05
LATEST
GSK’s Blenrep Scores World-First Approval in UK for Multiple Myeloma
2025-04-17
Exosomes: The Small Couriers Moving Beyond Traditional Drug Delivery
2025-04-17
Trump Administration’s CDC Layoffs Shutter STD Lab, Sending Ripples Through Biotech and Global Health
2025-04-17
Fake Ozempic Floods Market as FDA Warns Patients to Check Authenticity of Prescriptions
2025-04-16
NIH Facing $20 Billion Budget Cut and Potential Consolidation in 2026
2025-04-16
Trump Administration Budget Proposal Includes $20 Billion Cut to NIH by 2026 and Agency Reorganization
2025-04-16
Robert F. Kennedy Jr.’s Proposed Budget Prioritizes Public Health, Environmental Protection, and Healthcare Reform
2025-04-16
EVENT
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
2025-04-26
SABPA OC/LA 17th Annual Biomedical Forum
Irvine, California, United States
2025-05-03
29th Taiwan Joint Cancer Conference 2025
Taipei, Taiwan
2025-05-05
Swiss Biotech Day 2025
Basel, Switzerland
Scroll to Top